AntlerA Leverages Precision-engineered Protein Therapeutic Platform to Harness Body’s Regenerative Potential

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

SAN FRANCISCO, Aug. 27, 2019 /PRNewswire/ — AntlerA is leveraging a precision-engineered programmable Wnt pathway agonist platform to develop drugs that address large unmet needs in the regenerative medicine area.

AntlerA’s technology platform is based on a decade long research activity conducted by its scientific founders Dr. Sachdev Sidhu and Dr. Stephane Angers both Professors at the University of Toronto.  They have designed antibody like molecules that behave like Wnt growth factors, by binding to and activating two classes of Wnt receptors, Frizzled (FZD) and LRP5/6, on the surface of cells. Wnt signaling pathways play a crucial role in stem cell proliferation and regeneration.  However, recombinant Wnt proteins are hard and expensive to make while the AntlerA drug molecules is a Wnt mimic and is  a new generation of precision engineered antibody-ilke molecules that are easy to express recombinantly at scale in a cost effective manner.  Further, these antibodies can be programmed to have a high degree of specificity, making them viable as a therapeutic.  AntlerA has developed a large library of antibodies that activate specific FZD and LRP5/6 receptor complexes to enable on demand activation  depending on the cell type.

A seminal publication today in eLife by the scientific founders describes the platform and the technology behind AntlerA’s drug molecules. “These precision engineered Wnt agonists already show promising results in activating gut stem cells and can potentially be used to treat irritable bowel disease (IBD) by regenerating the damaged intestinal lining. They can also be used to treat eye, lung, liver and bone degenerative diseases,” says Dr. Sekar Seshagiri, CSO of AntlerA Therapeutics.

Emerge Ventures, Singapore is providing seed funding and incubation support to AntlerA through its Life Sciences fund.  “We are excited about AntlerA programmable activation technology and the promising results observed in activation of stem cells that can lead to development of therapeutics across multiple diseases,” says Mr. Mahesh Pratapneni, Founder and President of Emerge Ventures.

About AntlerA Therapeutics, Inc.

AntlerA Therapeutics is a regenerative medicines company, with labs in Toronto and San Francisco, focused on developing novel protein therapeutics that function by modulating Wnt signaling and other developmental cellular signaling pathways with the goal to control tissue stem cells and unleash tissue repair and rejuvenation

For more information, please visit www.antlera.co

Contact:
AntlerA Therapeutics
info@antlera.com

View original content to download multimedia:http://www.prnewswire.com/news-releases/antlera-leverages-precision-engineered-protein-therapeutic-platform-to-harness-bodys-regenerative-potential-300907858.html

SOURCE AntlerA Therapeutics, Inc.

Staff

Recent Posts

Glucotrack Announces Reverse Stock Split Shareholder Approved Action Meets NASDAQ Panel Hearing Listing Requirements

1-for-60 reverse stock split to become effective as of the opening of trading on June…

3 hours ago

Sharecare introduces new interactive solutions to elevate health literacy and increase condition-specific treatment adherence

Utilizing augmented reality, artificial intelligence, and time-based visualization, Sharecare’s newest innovative tools help life sciences…

3 hours ago

RadioMedix Debuts Proprietary bench top ²¹²Pb Generator to Support Targeted Alpha Therapy Development

New bench top ²¹²Pb generator to expand clinical-grade isotope supply for targeted alpha therapy research…

3 hours ago

Fortrea Adopts Limited-Duration Stockholder Rights Plan

Board Committed to Protecting Long-Term Value for All StockholdersDURHAM, N.C., June 12, 2025 (GLOBE NEWSWIRE)…

3 hours ago

Shuttle Pharma Announces Proposed Reverse Stock Split as Part of Strategic Nasdaq Compliance Initiative

GAITHERSBURG, Md., June 12, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle…

3 hours ago

Fortrea Adopts Limited-Duration Stockholder Rights Plan

Board Committed to Protecting Long-Term Value for All StockholdersDURHAM, N.C., June 12, 2025 (GLOBE NEWSWIRE)…

3 hours ago